查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403510

2030 年人类血小板裂解物市场预测：按药物类型、给药途径、配销通路、最终用户和地区进行的全球分析

Human Platelet Lysate Market Forecasts to 2030 - Global Analysis By Drug Type, Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球人血小板裂解物市场规模为 5,375 万美元，预计到 2030 年将达到 8,029 万美元，预测期内复合年增长率为 5.9%。

人类血小板裂解物 (HPL) 是一种源自人类血小板的细胞培养补充品。含有血小板衍生生长因子（PDGF）、转化生长因子β（TGF-B）和类胰岛素生长因子（IGF）等生长因子，以及促进细胞存活和刺激组织再生的各种蛋白质。此外，与牛(FBS) 等传统细胞培养补充品相比，它具有许多优势。 HPL 需求不断增长是由于多种驱动因素​​，包括其安全性、效率和道德考虑。

美国国家医学图书馆发布的资料表明，人类血小板裂解物 (hPL) 的製造成本比牛更昂贵，而胎牛血清是人类血小板裂解物 (hPL) 的替代选择。

对细胞培养应用的需求不断成长

人类血小板裂解物因富含细胞生长和增殖所必需的生长因子和细胞激素而闻名，已成为传统血清培养基的绝佳替代品。它支持细胞增殖、维持细胞特性和促进组织再生的能力使其在再生医学、干细胞研究和组织工程中越来越多的采用。此外，对个人化医疗、基于细胞的治疗方法的日益关注以及基于细胞培养的药物研发发现的进步进一步增加了对人类血小板裂解物的需求。因此，将促进市场的成长。

製造成本高

人类血小板裂解物经历了复杂的製造过程，包括收集、处理和品管，导致与传统的基于血清的培养基相比，製造成本更高。如此高的成本限制了细胞培养应用中广泛商业性用途的承受能力和可用性，并可能阻碍其采用。结果，市场扩张受到阻碍。

再生医学的进展

人类血小板裂解物富含细胞增生和组织再生必需的生长因子和细胞激素，完美满足再生治疗的要求。随着再生医学的不断发展，HPL 已成为细胞培养中的重要辅助剂，可支持细胞增殖并维持组织再生所需的细胞特性。此外，其促进创伤治疗、刺激组织修復和帮助开发基于细胞的治疗方法的能力使人类血小板裂解物成为再生医学应用中的宝贵成分。

污染风险

儘管与牛(FBS) 相比，异种污染减少，但人类血小板裂解物具有人源产品传播病原体的潜在风险。细菌和病毒等污染物可能会损害人类血小板裂解物的品质和安全性，影响其在研究和临床环境中细胞培养应用的适用性。因此，这是市场拓展的主要障碍。

COVID-19 的影响

COVID-19 大流行最初造成了医疗保健行业的混乱和捐血限制，影响了 HPL 製造的原材料的可得性。供应链中断和实验室活动减少扰乱了 HPL 的製造和分销。然而，这场大流行凸显了基于细胞的疗法的重要性，并增加了人们对 HPL 发挥关键作用的再生医学和细胞培养应用的兴趣。随着医疗保健产业的适应，随着细胞治疗方法研究重点的增加，市场已经捲土重来，这可能会进一步推动对 HPL 的需求。

预计基于肝素的人类血小板裂解物部分在预测期内将是最大的

据估计，基于肝素的人类血小板裂解物部分占最大份额。肝素用于防止血小板采集和 HPL 製造过程中发生凝血，确保维持血小板完整性和生物活性。这种专门的 HPL 透过支持细胞生长、增殖和活力，为细胞培养应用带来好处。肝素配方可增强 HPL 功能，特别有益于各种生物医学领域，例如再生医学、干细胞研究和组织工程，在这些领域中，维持血小板生物活性对于获得最佳细胞培养结果至关重要。

医院药房业务预计在预测期内复合年增长率最高

预计医院药局业务在预测期内将出现良好成长。医院药局是向医疗机构、临床医生和研究人员提供人类血小板溶解产品的重要中介机构。这些药房在为再生医学、细胞治疗和研究等各种医疗应用提供人类血小板裂解物方面发挥着至关重要的作用。此外，这些药房确保人类血小板裂解物产品的可用性、品质和及时分发，促进其在临床环境和医院实验室中的使用。

比最大的地区

由于生物医学研究活动的活性化、再生医学投资的增加以及对细胞疗法的日益关注，亚太地区在预测期内占据了最大的市场占有率。中国、日本、韩国和印度等国家透过利用医疗基础设施和研究倡议的进步，为 HPL 市场的成长做出了重大贡献。此外，该地区蓬勃发展的生物製药产业，加上其对个人化医疗和再生疗法的关注，为HPL的采用提供了重要的机会，使亚太地区成为HPL在多种生物医学应用中应用的重要场所。 。

复合年增长率最高的地区：

由于先进的医疗基础设施、强劲的生物製药行业以及对生物医学研究的大量投资，预计北美在预测期内将实现盈利增长。对个人化医疗的重视和对细胞疗法日益增长的需求正在推动 HPL 在各种生物医学应用中的使用。此外，北美已成为以尖端研发为特征的关键地区，并为 HPL 在生物医学研究和临床环境中广泛采用奠定了坚实的基础。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球人类血小板裂解物市场：依药物类型

  • 基于肝素的人类血小板裂解物
  • 无肝素人血小板裂解物
  • 其他类型

第六章全球人类血小板裂解物市场：依给药途径

  • 口服
  • 用于吸入
  • 其他给药途径

第七章全球人血小板裂解物市场：按配销通路

  • 医院药房
  • 药局
  • 零售店
  • 网路药房

第八章全球人类血小板裂解物市场：依最终用户分类

  • 治疗性的
  • 研究/学术机构
  • 製药和生物技术公司
  • 其他最终用户

第九章全球人类血小板裂解物市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • Abbott Laboratories
  • Astrazeneca Plc.
  • Acella Pharmaceuticals LLC
  • Cipla Limited
  • Glenmark Pharmaceuticals Limited
  • Dabur India Ltd
  • Johnson and Johnson
  • Glenmark Pharmaceuticals Limited
  • Merck KGaA
  • Pfizer Inc.
  • Novartis International AG
  • Sanofi SA
  • Vernalis plc
  • Aurobindo Pharma Ltd
  • The Himalaya Drug Company
  • Beckman Coulter Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Reckitt Benckiser Group PLC
  • Acadia Pharmaceuticals Inc.
  • Biocon
Product Code: SMRC24735

According to Stratistics MRC, the Global Human Platelet Lysate Market is accounted for $53.75 million in 2023 and is expected to reach $80.29 million by 2030 growing at a CAGR of 5.9% during the forecast period. Human Platelet Lysate (HPL) is a cell culture supplement derived from human blood platelets. It contains growth factors like platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-B), insulin-like growth factor (IGF), and various other proteins that promote cell survival and stimulate tissue regeneration. Moreover, it offers numerous advantages over traditional cell culture supplements like foetal bovine serum (FBS). The growing demand for HPL can be attributed to several driving factors, including its safety, efficiency, and ethical considerations.

According to data published on National Library of Medicine, stated that human platelet lysate (hPL) has higher production cost than foetal bovine serum, which is an alternative option of human platelet lysate (hPL).

Market Dynamics:

Driver:

Increasing demand in cell culture applications

Human platelet lysate, renowned for its rich composition of growth factors and cytokines essential for cell growth and proliferation, has emerged as a superior alternative to traditional serum-based media. Its ability to support cell expansion, maintain cellular properties, and promote tissue regeneration has led to increased adoption in regenerative medicine, stem cell research, and tissue engineering. Moreover, the heightened focus on personalised medicine, cell-based therapies, and advancements in drug discovery utilising cell cultures further amplifies the need for human platelet lysate. Therefore, it will propel market growth.

Restraint:

High production costs

The complex manufacturing process involving the collection, processing, and quality control measures for human platelet lysate results in elevated production expenses compared to traditional serum-based media. These higher costs limit its affordability and accessibility for widespread commercial use in cell culture applications, potentially hindering its adoption. As a result, it will hamper market expansion.

Opportunity:

Advancements in regenerative medicine

The human platelet lysate's rich composition of growth factors and cytokines essential for cell growth and tissue regeneration aligns perfectly with the requirements of regenerative therapies. As regenerative medicine continues to evolve, HPL emerges as a crucial supplement in cell culture, supporting cell proliferation and maintaining cellular properties necessary for tissue regeneration. Furthermore, its ability to enhance wound healing, stimulate tissue repair, and aid in the development of cell-based therapies positions human platelet lysate as a valuable component in regenerative medicine applications.

Threat:

Contamination risks

Despite reduced xenogeneic contamination compared to foetal bovine serum (FBS), human platelet lysate carries the potential risk of pathogen transmission from human-derived products. Contaminants, such as bacteria or viruses, could compromise the quality and safety of human platelet lysate, impacting its suitability for cell culture applications in research and clinical settings. Hence, it acts as a significant barrier to market expansion.

COVID-19 Impact

The COVID-19 pandemic initially caused disruptions in the healthcare sector and restrictions on blood donations, which affected the availability of raw materials for HPL production. Supply chain disruptions and reduced laboratory activities hindered its manufacturing and distribution. However, the pandemic underscored the importance of cell-based therapies, boosting interest in regenerative medicine and cell culture applications where HPL plays a crucial role. As the healthcare sector adapted, the market witnessed a resurgence due to increased research focus on cell-based treatments, potentially driving further demand for HPL.

The heparin-based human platelet lysate segment is expected to be the largest during the forecast period

The heparin-based human platelet lysate segment is estimated to hold the largest share. Heparin serves to prevent clotting during platelet collection and HPL production, ensuring the maintenance of platelet integrity and bioactivity. This specialised variant of HPL offers advantages in cell culture applications by supporting cell growth, proliferation, and viability. The inclusion of heparin enhances the functionality of HPL, making it particularly beneficial in various biomedical fields, including regenerative medicine, stem cell research, and tissue engineering, where uninterrupted platelet bioactivity is essential for optimal cell culture outcomes.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

The hospital pharmacies segment is anticipated to have lucrative growth during the forecast period. Hospital pharmacies serve as crucial intermediaries, providing human platelet lysate products to healthcare facilities, clinicians, and researchers. These pharmacies play a pivotal role in supplying human platelet lysate for various medical applications, including regenerative medicine, cell therapy, and research endeavours. Moreover, they ensure the availability, quality, and timely distribution of human platelet lysate products, facilitating their use in clinical settings and research laboratories within hospitals.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to rising biomedical research activities, increasing investments in regenerative medicine, and a growing focus on cell-based therapies. Countries such as China, Japan, South Korea, and India are prominent contributors to HPL market growth, leveraging advancements in healthcare infrastructure and research initiatives. Furthermore, the region's burgeoning biopharmaceutical industry, combined with the emphasis on personalised medicine and regenerative therapies, offers substantial opportunities for HPL adoption, shaping the Asia-Pacific region as a significant hub for HPL utilisation in diverse biomedical applications.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period due to advanced healthcare infrastructure, a robust biopharmaceutical industry, and substantial investments in biomedical research. Growing emphasis on personalised medicine and the escalating demand for cell-based therapies bolster the utilisation of HPL in various biomedical applications. Furthermore, North America stands as a key region, characterised by its cutting-edge developments and a strong foundation for the widespread adoption of HPL in biomedical research and clinical settings.

Key players in the market:

Some of the key players in the Human Platelet Lysate Market include Abbott Laboratories, Astrazeneca Plc., Acella Pharmaceuticals LLC, Cipla Limited, Glenmark Pharmaceuticals Limited, Dabur India Ltd, Johnson and Johnson, Glenmark Pharmaceuticals Limited, Merck KGaA, Pfizer Inc., Novartis International AG, Sanofi SA, Vernalis plc, Aurobindo Pharma Ltd, The Himalaya Drug Company, Beckman Coulter Inc., Sun Pharmaceutical Industries Ltd., Reckitt Benckiser Group PLC, Acadia Pharmaceuticals Inc. and Biocon.

Key Developments:

In June 2023, PL BioScience GmbH entered into a Patent License and Assignment Agreement with French company Macopharma S.A.S., granting PL BioScience a worldwide license under Macopharma's patents and introducing PL BioScience to Macopharma's HPL customers for future orders.

In August 2022, StemCyte, Inc. obtained approval from U.S. FDA for their Phase II clinical trial for Post-COVID Syndrome using umbilical cord blood stem cell therapy.

In June 2021, Captivate Bio has signed a partnership agreement with PL BioScience GmbH to exclusively distribute ELAREM human platelet lysate products in the US and Canada, expanding their HPL offerings and enhancing PL BioScience's market presence in North America.

Drug Types Covered:

  • Heparin-based Human Platelet Lysate
  • Heparin-free Human Platelet Lysate
  • Other Types

Route of Administrations Covered:

  • Oral
  • Inhalational
  • Other Routes of Administration

Distribution Channels Covered:

  • Hospital Pharmacies
  • Drug Store
  • Retail Store
  • Online Pharmacies

End Users Covered:

  • Therapeutic
  • Pharmaceutical and Biotechnology Companies
  • Research and Academic Institutions
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Human Platelet Lysate Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Heparin-based Human Platelet Lysate
  • 5.3 Heparin-free Human Platelet Lysate
  • 5.4 Other Types

6 Global Human Platelet Lysate Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Oral
  • 6.3 Inhalational
  • 6.4 Other Routes of Administration

7 Global Human Platelet Lysate Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Drug Store
  • 7.4 Retail Store
  • 7.5 Online Pharmacies

8 Global Human Platelet Lysate Market, By End User

  • 8.1 Introduction
  • 8.2 Therapeutic
  • 8.3 Research and Academic Institutions
  • 8.4 Pharmaceutical and Biotechnology Companies
  • 8.5 Other End Users

9 Global Human Platelet Lysate Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott Laboratories
  • 11.2 Astrazeneca Plc.
  • 11.3 Acella Pharmaceuticals LLC
  • 11.4 Cipla Limited
  • 11.5 Glenmark Pharmaceuticals Limited
  • 11.6 Dabur India Ltd
  • 11.7 Johnson and Johnson
  • 11.8 Glenmark Pharmaceuticals Limited
  • 11.9 Merck KGaA
  • 11.10 Pfizer Inc.
  • 11.11 Novartis International AG
  • 11.12 Sanofi SA
  • 11.13 Vernalis plc
  • 11.14 Aurobindo Pharma Ltd
  • 11.15 The Himalaya Drug Company
  • 11.16 Beckman Coulter Inc.
  • 11.17 Sun Pharmaceutical Industries Ltd.
  • 11.18 Reckitt Benckiser Group PLC
  • 11.19 Acadia Pharmaceuticals Inc.
  • 11.20 Biocon

List of Tables

  • Table 1 Global Human Platelet Lysate Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Human Platelet Lysate Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 3 Global Human Platelet Lysate Market Outlook, By Heparin-based Human Platelet Lysate (2021-2030) ($MN)
  • Table 4 Global Human Platelet Lysate Market Outlook, By Heparin-free Human Platelet Lysate (2021-2030) ($MN)
  • Table 5 Global Human Platelet Lysate Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 6 Global Human Platelet Lysate Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 7 Global Human Platelet Lysate Market Outlook, By Oral (2021-2030) ($MN)
  • Table 8 Global Human Platelet Lysate Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 9 Global Human Platelet Lysate Market Outlook, By Other Routes of Administration (2021-2030) ($MN)
  • Table 10 Global Human Platelet Lysate Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 11 Global Human Platelet Lysate Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 12 Global Human Platelet Lysate Market Outlook, By Drug Store (2021-2030) ($MN)
  • Table 13 Global Human Platelet Lysate Market Outlook, By Retail Store (2021-2030) ($MN)
  • Table 14 Global Human Platelet Lysate Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 15 Global Human Platelet Lysate Market Outlook, By End User (2021-2030) ($MN)
  • Table 16 Global Human Platelet Lysate Market Outlook, By Therapeutic (2021-2030) ($MN)
  • Table 17 Global Human Platelet Lysate Market Outlook, By Research and Academic Institutions (2021-2030) ($MN)
  • Table 18 Global Human Platelet Lysate Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 19 Global Human Platelet Lysate Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 20 North America Human Platelet Lysate Market Outlook, By Country (2021-2030) ($MN)
  • Table 21 North America Human Platelet Lysate Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 22 North America Human Platelet Lysate Market Outlook, By Heparin-based Human Platelet Lysate (2021-2030) ($MN)
  • Table 23 North America Human Platelet Lysate Market Outlook, By Heparin-free Human Platelet Lysate (2021-2030) ($MN)
  • Table 24 North America Human Platelet Lysate Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 25 North America Human Platelet Lysate Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 26 North America Human Platelet Lysate Market Outlook, By Oral (2021-2030) ($MN)
  • Table 27 North America Human Platelet Lysate Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 28 North America Human Platelet Lysate Market Outlook, By Other Routes of Administration (2021-2030) ($MN)
  • Table 29 North America Human Platelet Lysate Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 30 North America Human Platelet Lysate Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 31 North America Human Platelet Lysate Market Outlook, By Drug Store (2021-2030) ($MN)
  • Table 32 North America Human Platelet Lysate Market Outlook, By Retail Store (2021-2030) ($MN)
  • Table 33 North America Human Platelet Lysate Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 34 North America Human Platelet Lysate Market Outlook, By End User (2021-2030) ($MN)
  • Table 35 North America Human Platelet Lysate Market Outlook, By Therapeutic (2021-2030) ($MN)
  • Table 36 North America Human Platelet Lysate Market Outlook, By Research and Academic Institutions (2021-2030) ($MN)
  • Table 37 North America Human Platelet Lysate Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 38 North America Human Platelet Lysate Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 39 Europe Human Platelet Lysate Market Outlook, By Country (2021-2030) ($MN)
  • Table 40 Europe Human Platelet Lysate Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 41 Europe Human Platelet Lysate Market Outlook, By Heparin-based Human Platelet Lysate (2021-2030) ($MN)
  • Table 42 Europe Human Platelet Lysate Market Outlook, By Heparin-free Human Platelet Lysate (2021-2030) ($MN)
  • Table 43 Europe Human Platelet Lysate Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 44 Europe Human Platelet Lysate Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 45 Europe Human Platelet Lysate Market Outlook, By Oral (2021-2030) ($MN)
  • Table 46 Europe Human Platelet Lysate Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 47 Europe Human Platelet Lysate Market Outlook, By Other Routes of Administration (2021-2030) ($MN)
  • Table 48 Europe Human Platelet Lysate Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 49 Europe Human Platelet Lysate Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 50 Europe Human Platelet Lysate Market Outlook, By Drug Store (2021-2030) ($MN)
  • Table 51 Europe Human Platelet Lysate Market Outlook, By Retail Store (2021-2030) ($MN)
  • Table 52 Europe Human Platelet Lysate Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 53 Europe Human Platelet Lysate Market Outlook, By End User (2021-2030) ($MN)
  • Table 54 Europe Human Platelet Lysate Market Outlook, By Therapeutic (2021-2030) ($MN)
  • Table 55 Europe Human Platelet Lysate Market Outlook, By Research and Academic Institutions (2021-2030) ($MN)
  • Table 56 Europe Human Platelet Lysate Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 57 Europe Human Platelet Lysate Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 58 Asia Pacific Human Platelet Lysate Market Outlook, By Country (2021-2030) ($MN)
  • Table 59 Asia Pacific Human Platelet Lysate Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 60 Asia Pacific Human Platelet Lysate Market Outlook, By Heparin-based Human Platelet Lysate (2021-2030) ($MN)
  • Table 61 Asia Pacific Human Platelet Lysate Market Outlook, By Heparin-free Human Platelet Lysate (2021-2030) ($MN)
  • Table 62 Asia Pacific Human Platelet Lysate Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 63 Asia Pacific Human Platelet Lysate Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 64 Asia Pacific Human Platelet Lysate Market Outlook, By Oral (2021-2030) ($MN)
  • Table 65 Asia Pacific Human Platelet Lysate Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 66 Asia Pacific Human Platelet Lysate Market Outlook, By Other Routes of Administration (2021-2030) ($MN)
  • Table 67 Asia Pacific Human Platelet Lysate Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 68 Asia Pacific Human Platelet Lysate Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 69 Asia Pacific Human Platelet Lysate Market Outlook, By Drug Store (2021-2030) ($MN)
  • Table 70 Asia Pacific Human Platelet Lysate Market Outlook, By Retail Store (2021-2030) ($MN)
  • Table 71 Asia Pacific Human Platelet Lysate Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 72 Asia Pacific Human Platelet Lysate Market Outlook, By End User (2021-2030) ($MN)
  • Table 73 Asia Pacific Human Platelet Lysate Market Outlook, By Therapeutic (2021-2030) ($MN)
  • Table 74 Asia Pacific Human Platelet Lysate Market Outlook, By Research and Academic Institutions (2021-2030) ($MN)
  • Table 75 Asia Pacific Human Platelet Lysate Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 76 Asia Pacific Human Platelet Lysate Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 77 South America Human Platelet Lysate Market Outlook, By Country (2021-2030) ($MN)
  • Table 78 South America Human Platelet Lysate Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 79 South America Human Platelet Lysate Market Outlook, By Heparin-based Human Platelet Lysate (2021-2030) ($MN)
  • Table 80 South America Human Platelet Lysate Market Outlook, By Heparin-free Human Platelet Lysate (2021-2030) ($MN)
  • Table 81 South America Human Platelet Lysate Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 82 South America Human Platelet Lysate Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 83 South America Human Platelet Lysate Market Outlook, By Oral (2021-2030) ($MN)
  • Table 84 South America Human Platelet Lysate Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 85 South America Human Platelet Lysate Market Outlook, By Other Routes of Administration (2021-2030) ($MN)
  • Table 86 South America Human Platelet Lysate Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 87 South America Human Platelet Lysate Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 88 South America Human Platelet Lysate Market Outlook, By Drug Store (2021-2030) ($MN)
  • Table 89 South America Human Platelet Lysate Market Outlook, By Retail Store (2021-2030) ($MN)
  • Table 90 South America Human Platelet Lysate Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 91 South America Human Platelet Lysate Market Outlook, By End User (2021-2030) ($MN)
  • Table 92 South America Human Platelet Lysate Market Outlook, By Therapeutic (2021-2030) ($MN)
  • Table 93 South America Human Platelet Lysate Market Outlook, By Research and Academic Institutions (2021-2030) ($MN)
  • Table 94 South America Human Platelet Lysate Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 95 South America Human Platelet Lysate Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 96 Middle East & Africa Human Platelet Lysate Market Outlook, By Country (2021-2030) ($MN)
  • Table 97 Middle East & Africa Human Platelet Lysate Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 98 Middle East & Africa Human Platelet Lysate Market Outlook, By Heparin-based Human Platelet Lysate (2021-2030) ($MN)
  • Table 99 Middle East & Africa Human Platelet Lysate Market Outlook, By Heparin-free Human Platelet Lysate (2021-2030) ($MN)
  • Table 100 Middle East & Africa Human Platelet Lysate Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 101 Middle East & Africa Human Platelet Lysate Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 102 Middle East & Africa Human Platelet Lysate Market Outlook, By Oral (2021-2030) ($MN)
  • Table 103 Middle East & Africa Human Platelet Lysate Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 104 Middle East & Africa Human Platelet Lysate Market Outlook, By Other Routes of Administration (2021-2030) ($MN)
  • Table 105 Middle East & Africa Human Platelet Lysate Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 106 Middle East & Africa Human Platelet Lysate Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 107 Middle East & Africa Human Platelet Lysate Market Outlook, By Drug Store (2021-2030) ($MN)
  • Table 108 Middle East & Africa Human Platelet Lysate Market Outlook, By Retail Store (2021-2030) ($MN)
  • Table 109 Middle East & Africa Human Platelet Lysate Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 110 Middle East & Africa Human Platelet Lysate Market Outlook, By End User (2021-2030) ($MN)
  • Table 111 Middle East & Africa Human Platelet Lysate Market Outlook, By Therapeutic (2021-2030) ($MN)
  • Table 112 Middle East & Africa Human Platelet Lysate Market Outlook, By Research and Academic Institutions (2021-2030) ($MN)
  • Table 113 Middle East & Africa Human Platelet Lysate Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 114 Middle East & Africa Human Platelet Lysate Market Outlook, By Other End Users (2021-2030) ($MN)